Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema

Manuel Diaz-Llopis, Patricia Udaondo, Jose Maria Millán, J Fernando Arevalo

Department of Ophthalmology, University and Polytechnic Hospital La Fe of Valencia, 46009 Valencia, Spain
Jose Maria Millán, Department of Genetics, Hospital Universitario La Fe of Valencia, 46009 Valencia, Spain
J Fernando Arevalo, Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, United States
J Fernando Arevalo, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia

Author contributions: All the authors contributed to this work.

Correspondence to: Manuel Diaz-Llopis, MD, Department of Ophthalmology, University and Polytechnic Hospital La Fe of Valencia, Avenida Campanar 21, 46009 Valencia, Spain. manuel.diaz@uv.es

Telephone: +34-666-530085 Fax: +34-963-606848
Received: December 27, 2012 Revised: September 7, 2013
Accepted: September 14, 2013
Published online: December 15, 2013

Abstract

The aim of this paper is to determine the role of enzymatic vitrectomy performed by intravitreal injection of autologous plasmin enzyme (APE) in the management of diabetic retinopathy and diabetic macular edema (DME). Diabetic patients with proliferative diabetic retinopathy or DME and evident posterior hyaloid adherence to the retinal surface were included. All cases were treated with an initial intravitreal injection of APE and reevaluated one month later, measuring changes in best-corrected visual acuity (BCVA), macular thickness and the status of the posterior hyaloid. A second APE injection was performed in cases with no evident posterior vitreous detachment (PVD) after the initial treatment. Sixty-three eyes were included in the present review. A complete PVD appeared in 38% of cases (24 eyes) after one injection of plasmin and the total increased to 51% (32 eyes) after the second injection, separated at least by one month. The central macular thickness improved in all cases (100%) and BCVA in 89%. Finally, in 50% of eyes with proliferative diabetic retinopathy, a high reduction of new vessels regression was observed. Enzymatic vitrectomy could be considered a good therapeutic alternative in diabetic retinopathy and macular edema.

Diaz-Llopis M, Udaondo P, Millán JM, Arevalo JF. Enzymatic vitrectomy for diabetic retinopathy and diabetic macular edema. World J Diabetes 2013; 4(6): 319-323 Available from: URL: http://www.wjgnet.com/1948-9358/full/v4/i6/319.htm DOI: http://dx.doi.org/10.4239/wjd.v4.i6.319

INTRODUCTION

Diabetes mellitus (DM) causes diabetic retinopathy (DR) and diabetic macular edema (DME) as a consequence of diabetic microangiopathy. Nowadays, DM might be considered as a pandemic disease with its incidence and prevalence increasing exponentially, even becoming epidemic. The aim of the present review was to analyze the clinical efficacy of the intravitreal injection of autologous plasmin enzyme in the treatment of diabetic retinopathy and diabetic macular edema and to determine the role of enzymatic vitrectomy as a therapeutic approach in such cases.

© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Enzymatic vitrectomy; Autologous plasmin; Diabetic macular edema; Diabetic retinopathy

Core tip: Diabetes mellitus might be considered as a pandemic disease with its incidence and prevalence increasing exponentially, even becoming epidemic. The aim of the present review was to analyze the clinical efficacy of the intravitreal injection of autologous plasmin enzyme in the treatment of diabetic retinopathy and diabetic macular edema and to determine the role of enzymatic vitrectomy as a therapeutic approach in such cases.
evolution of the systemic disease, with nearly 100% of patients showing some degree of diabetic retinopathy after 20 years of evolution. On the other hand, DME develops in 14%-25% of patients after 10 years of DM[3]–[5]. DR is a major cause of visual loss and a leading cause of blindness, whereas DME is the most common cause of visual loss in people under 50 years of age in developed countries[1–3].

Retinal neovascularization is a significant risk factor for severe visual loss in patients with DM, with optic disk new vessels as the maximum expression of such risk[6]. Laser photocoagulation has been the mainstay of treatment for DME and DR, but only 60% of patients with proliferative diabetic retinopathy (PDR) respond to panretinal photocoagulation, with regression of the neovascularization within 3 mo[7–9]. Laser photocoagulation mainly preserves vision rather than restoring it in cases of DME and PDR[7,9,10].

More recently, new therapeutic approaches have been developed for the management of both PDR and DME, including intravitreal injections of steroids (triamcinolone, sustained release intravitreal corticosteroid implant) or vascular endothelial factor inhibitors (VEGF), such as pegaptanib (Macugen; OSI pharmaceuticals, Melville, NY), bevacizumab (Avastin; Genentech, San Francisco, CA), ranibizumab (Lucentis; Genentech, San Francisco, CA) and aflibercept (Eylea, Regeneron Pharmaceutical, Inc, Tarrytown, NY), achieving vision improvement in a significant number of patients[10–12,13].

The incidence of DME and the progression rate of PDR are significantly lower in patients with spontaneous or surgical posterior vitreous detachment (PVD). It has been demonstrated that the adherence of the posterior hyaloid to the inner limiting membrane plays an important role in the development of DME and also in the growth of new vessels and its consequences, vitreous hemorrhage and tractional retinal detachment[13–17].

Enzymatic vitrectomy or pharmacological vitreolysis by intravitreal injection of autologous plasmin enzyme (APE) has been proposed as an effective neoadjuvant treatment for vitreous surgery by facilitating the surgical detachment of the posterior hyaloid and vitreoretinal membranes[18,19].

Plasmin, a serine protease, is active against laminin and fibronectin, located in the interface between the posterior vitreous cortex and the internal limiting membrane, and is responsible for the attachment of the vitreous to the retinal surface[20].

The aim of the present review was to analyze the clinical efficacy of the intravitreal injection of APE in the treatment of DR and DME and to determine the role of enzymatic vitrectomy as a therapeutic approach in such cases.

RESEARCH

The primary outcome was considered as the proportion of patients with a complete PVD following intravitreal injection of APE. The secondary outcomes were: number of patients with improvement in visual acuity and/or central macular thickness measured by optical coherence tomography (OCT); regression of new vessels in cases of PDR; and safety assessment of intravitreal injection of APE.

Before the injection of APE, all patients underwent a comprehensive ocular examination, including best corrected visual acuity (BCVA), slit-lamp examination, tonometry, indirect ophthalmoscopy, macular thickness measurement and assessment of posterior hyaloid status by OCT, color photographs and fluorescein angiography.

APE injection

A total volume of 0.2 mL of APE was obtained by a simplified method[21] and prepared 45 min prior to injection, sterilized through a 0.22 µm pore filter. Patients received unilateral intravitreal injections of APE through pars plana using a 30-gauge needle according to the routine procedure of intravitreal injections.

TREATMENT

A total of 63 eyes of 52 patients were included in the present study. Of them, 10 eyes showed PDR with optic disk new vessels and 53 eyes showed DME (33 refractory DME cases and 20 treatment-naïve patients).

Primary outcome: posterior vitreous detachment

A complete PVD appeared in 38% of cases (24 eyes) after one injection of plasmin and the total increased to 51% (32 eyes) after the second injection, separated at least by one month.

Secondary outcomes

Central macular thickness decreased in all cases with DME, even in cases without PVD following intravitreal injections of APE. BCVA improved in 89% of the treated eyes (56) (Figures 1, 2).

In cases with PDR, a highly significant regression in the new vessel area was observed in 5 cases (50%) (Figure 3); in 2 cases a partial regression was evidenced (20%), whereas the 3 remaining cases did not experience any change (30%).

Safety profile

The treatment was well tolerated in all cases. No side effects were evidenced through the follow-up (uveitis, vitreous hemorrhage, cataract, ocular hypertension or retinal detachment).

DISCUSSION

The analyzed data suggested a possible role for enzymatic vitreolysis by intravitreal injection of APE for the management of PDR and DME. The efficacy of this
procedure is related to the biochemical modification of the vitreous composition induced by the enzymatic separation or weakening of the union between the posterior vitreous cortex and the internal limiting membrane, leading to the development of PVD, and the liquefaction of the vitreous gel\(^\text{22}\). This procedure is dynamic with an important impact on the vitreous cavity. PVD not only has a protective role in a variety of retinal disorders, but also induces changes in the intraocular concentration of molecules, including VEGF, and increases intravitreal molecular diffusion coefficients and intravitreal oxygen levels\(^\text{23-26}\); this could also contribute to the good results obtained with this therapy.

APE employed in the present study was obtained by a simplified method and can be prepared in the operating room 45 min prior to the intravitreal injection. This constitutes a significant advantage compared to previously described techniques that required a longer and more...
expensive procedure. On the other hand, the method we propose has a wide variability and we cannot exactly recognize the concentration of APE that is injected and it depends on the plasminogen levels in each patient.\textsuperscript{27-30}

We achieved an overall efficacy of 50% in terms of inducing PVD in cases of DME and PDR, without any significant ocular side effects.

In conclusion, enzymatic vitrectomy performed by the intravitreal injection of APE might be effective and could be considered as an alternative for diabetic patients before performing other treatments, such as intravitreal injections of anti-VEGF or steroids, surgical vitrectomy or laser. Further studies are necessary to assess the efficacy and safety for the longer term and most convenient therapeutic strategy, including association of treatments, in diabetic patients to get better and more permanent results.

REFERENCES

1. DCCT Research Group. The effect of intensive treatment of diabetes in the development and progression of long-term complications in insulin-dependent diabetes. N Engl J Med 1993; 329: 977-986 [DOI: 10.1056/NEJM1993093129114]

2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16 [PMID: 7831044]

3. Centers for Disease Control. Available from: URL: http://www.cdc.gov/diabetes/news/docs/dpp.htm

4. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular edema: a systematic review. Eye (Lond) 2004; 18: 963-983 [DOI: 10.1038/sj.eye.6701476]

5. Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984; 91: 1-9 [PMID: 6709312]

6. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 823-833 [PMID: 2062515]

7. Lee CM, Olik R. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology 1991; 98: 1594-1602 [PMID: 1961650]

8. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research group. Arch Ophthalmol 1985; 103: 1796-1806 [PMID: 2866759 DOI: 10.1001/archopht.1985.0105012005011]

9. Vander JF, Duker JS, Bersen WE, Brown GC, McNamara JA, Rosenberg RB. Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991; 98: 1575-1579 [PMID: 1961647]

10. Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular edema: an indirect comparison in a systematic review. BMJ 2012; 345: e5182 [PMID: 22890029 DOI: 10.1136/bmj.e5182]

11. Massin P, Audren F, Haouchine B, Ergnay A, Bergmann JF, Benosman R, Caulin C, Gaudric A. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-224; discussion 224-225 [PMID: 15019365 DOI: 10.1016/j.ophtha.2003.05.037]

12. Haller JA, Kuppermann BD, Blumenkranz MS, Williams GA, Weinberg DV, Chou C, Whitcup SM. Randomized con-
efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest Ophthalmol Vis Sci 2004; 45: 3286-3290 [PMID: 15326153 DOI: 10.1167/iovs.04-0026]

30 Ulrich JN, Spannagl M, Kampik A, Gandorfer A. Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders. Clin Experiment Ophthalmol 2008; 36: 431-436 [PMID: 18939350]

P- Reviewers: Le YZ, Ido Y, Romero-Aroca P S- Editor: Wen LL L- Editor: Roemmele A E- Editor: Lu Y
